T Demir1, H Onay2, D B Savage3, E Temeloglu4, A K Uzum5, P Kadioglu4, C Altay6, S Ozen2,7, L Demir8, U Cavdar1, B Akinci9. 1. Dokuz Eylul University, Division of Endocrinology, Izmir, Turkey. 2. Ege University, Department of Medical Genetics, Izmir, Turkey. 3. University of Cambridge, Metabolic Research Laboratories, Wellcome Trust-Medical Research Council Institute of Metabolic Science, Cambridge, UK. 4. Istanbul University, Cerrahpasa Medical Faculty, Division of Endocrinology, Istanbul, Turkey. 5. Istanbul University, Capa Medical Faculty, Division of Endocrinology, Istanbul, Turkey. 6. Dokuz Eylul University, Department of Radiology, Izmir, Turkey. 7. Ege University, Division of Paediatric Endocrinology, Izmir, Turkey. 8. Ataturk Training Hospital, Department of Biochemistry, Izmir, Turkey. 9. Dokuz Eylul University, Division of Endocrinology, Izmir, Turkey. barisakincimd@gmail.com.
Abstract
AIMS: To describe the phenotype associated with a novel heterozygous missense PPARG mutation discovered in a Turkish family and to compare the fat distribution and metabolic characteristics of subjects with the peroxisome proliferator activator receptor -γ (PPARG) mutation with those of a cluster of patients with familial partial lipodystrophy with classic codon 482 Lamin A/C (LMNA) mutations. METHODS: The study involved four subjects with familial partial lipodystrophy who had a novel PPARG mutation (H449L) and six subjects with classic codon 482 LMNA mutations (R482W). RESULTS: Compared with subjects with LMNA R482W mutation, fat loss was generally less prominent in subjects with the PPARG H449L mutation. Partial fat loss was limited to the extremities, whilst truncal fat mass was preserved. The PPARG H449L mutation was associated with insulin resistance, hypertriglyceridaemia and non-alcoholic fatty liver disease in all affected subjects, but the severity was variable. Three out of four mutation carriers had overt diabetes or impaired glucose tolerance. Pioglitazone therapy in these three individuals resulted in a modest improvement in their metabolic control, and regular menstrual cycles in the two female subjects. CONCLUSIONS: We suggest that relatively modest fat loss in patients with PPARG mutations may render the recognition of the syndrome more difficult in routine clinical practice. The PPARG H449L mutation is associated with insulin resistance and metabolic complications, but their severity is variable among the affected subjects.
AIMS: To describe the phenotype associated with a novel heterozygous missense PPARG mutation discovered in a Turkish family and to compare the fat distribution and metabolic characteristics of subjects with the peroxisome proliferator activator receptor -γ (PPARG) mutation with those of a cluster of patients with familial partial lipodystrophy with classic codon 482 Lamin A/C (LMNA) mutations. METHODS: The study involved four subjects with familial partial lipodystrophy who had a novel PPARG mutation (H449L) and six subjects with classic codon 482 LMNA mutations (R482W). RESULTS: Compared with subjects with LMNAR482W mutation, fat loss was generally less prominent in subjects with the PPARGH449L mutation. Partial fat loss was limited to the extremities, whilst truncal fat mass was preserved. The PPARGH449L mutation was associated with insulin resistance, hypertriglyceridaemia and non-alcoholic fatty liver disease in all affected subjects, but the severity was variable. Three out of four mutation carriers had overt diabetes or impaired glucose tolerance. Pioglitazone therapy in these three individuals resulted in a modest improvement in their metabolic control, and regular menstrual cycles in the two female subjects. CONCLUSIONS: We suggest that relatively modest fat loss in patients with PPARG mutations may render the recognition of the syndrome more difficult in routine clinical practice. The PPARGH449L mutation is associated with insulin resistance and metabolic complications, but their severity is variable among the affected subjects.
Authors: Alba Rojano-Toimil; Jesús Rivera-Esteban; Ramiro Manzano-Nuñez; Juan Bañares; David Martinez Selva; Pablo Gabriel-Medina; Roser Ferrer; Juan M Pericàs; Andreea Ciudin Journal: J Clin Med Date: 2022-06-08 Impact factor: 4.964
Authors: Maura Agostini; Erik Schoenmakers; Junaid Beig; Louise Fairall; Istvan Szatmari; Odelia Rajanayagam; Frederick W Muskett; Claire Adams; A David Marais; Stephen O'Rahilly; Robert K Semple; Laszlo Nagy; Amit R Majithia; John W R Schwabe; Dirk J Blom; Rinki Murphy; Krishna Chatterjee; David B Savage Journal: Diabetes Date: 2018-04-05 Impact factor: 9.461
Authors: Ben Tsuda; Maura Agostini; Keerthana Gnanapradeepan; Amit R Majithia; Robert Rice; Gina Peloso; Kashyap A Patel; Xiaolan Zhang; Marjoleine F Broekema; Nick Patterson; Marc Duby; Ted Sharpe; Eric Kalkhoven; Evan D Rosen; Inês Barroso; Sian Ellard; Sekar Kathiresan; Stephen O'Rahilly; Krishna Chatterjee; Jose C Florez; Tarjei Mikkelsen; David B Savage; David Altshuler Journal: Nat Genet Date: 2016-10-17 Impact factor: 38.330